A Phase 3 interventional study of Generic Ivermectin Lotion 0.5% and Sklice® (Ivermectin) Lotion 0.5% in Head Lice, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 6 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-20.
Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical study is designed to evaluate the clinical (therapeutic) effect of a generic ivermectin lotion 0.5% (Actavis Laboratories UT, Inc.) relative to that of the Food and Drug Administration (FDA) Reference Listed Drug (RLD) SKLICE® (ivermectin) lotion, 0.5% (Arbor Pharmaceuticals, LLC) in participants with active head lice infestation. Additionally, both the test and reference (that is; the RLD) treatments were tested for superiority to a placebo.
Participants will be randomized by household in a 3:3:1 ratio to receive generic ivermectin lotion 0.5%, Sklice (ivermectin) lotion 0.5%, or vehicle lotion.
Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
Drug: Generic Ivermectin Lotion 0.5%
Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
Drug: Sklice® (Ivermectin) Lotion 0.5%
Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
Drug: Vehicle Lotion
Topical lotion, generic formulation of the brand product.
Topical lotion, brand product.
Topical lotion, placebo. Has no active ingredient.
Percentage of Index Participants Who Were Considered a Treatment Success: PP Population
Treatment success was defined as the absence of live lice. Index participant was defined as the youngest household member who was randomized into the study. Therapeutic equivalence evaluation between test (generic ivermectin lotion 0.5%) and reference groups (Sklice \[ivermectin\] lotion 0.5%) was done in this endpoint, hence placebo group was not included.
Time frame: Day 15 ± 2
Percentage of Index Participants Who Were Considered a Treatment Success: mITT Population
Treatment success was defined as the absence of live lice. Index participant was defined as the youngest household member who was randomized into the study.
Time frame: Day 15 ± 2
Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: PP Population
Treatment success was defined as the absence of live lice. Non-index participant: Any household member who agreed to participate in the study but was not the youngest household member. Index participant: The youngest household member who was randomized into the study. Therapeutic equivalence evaluation between test (generic ivermectin lotion 0.5%) and reference groups (Sklice \[ivermectin\] lotion 0.5%) was done in this endpoint, hence placebo group was not included.
Time frame: Day 15 ± 2
Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: mITT Population
Treatment success was defined as the absence of live lice. Non-index participant: Any household member who agreed to participate in the study but was not the youngest household member. Index participant: The youngest household member who was randomized into the study.
Time frame: Day 15 ± 2
A total of 912 infested household participants were included and 911 (905 enrolled \[380 index + 525 non-index\] + 6 non-enrolled) were treated. Participants were randomized in 3:3:1 to generic ivermectin, Sklice (ivermectin), or vehicle lotion. 1 participant was considered randomized but not dispensed, so not included in any treatment arm.
| Milestone | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion | Vehicle Lotion |
|---|---|---|---|
| Started | 399 | 400 | 112 |
| Safety population | 399 | 400 | 112 |
| Modified intent-to-treat(mitt)population | 372 | 380 | 111 |
| Per-protocol (pp) population | 345 | 354 | 103 |
| Completed | 356 | 356 | 27 |
| Not completed | 43 | 44 | 85 |
| Withdrew: Need alternate therapy due to live lice | 17 | 25 | 81 |
| Withdrew: Lost to follow-up | 11 | 11 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 10 | 4 | 0 |
| Withdrew: Other than specified | 5 | 3 | 0 |
Treatment success was defined as the absence of live lice. Index participant was defined as the youngest household member who was randomized into the study. Therapeutic equivalence evaluation between test (generic ivermectin lotion 0.5%) and reference groups (Sklice \[ivermectin\] lotion 0.5%) was done in this endpoint, hence placebo group was not included.
| percentage of participants | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion |
|---|---|---|
| Percentage of Index Participants Who Were Considered a Treatment Success: PP Population | 90.9 | 89.0 |
Treatment success was defined as the absence of live lice. Index participant was defined as the youngest household member who was randomized into the study.
| percentage of participants | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion | Vehicle Lotion |
|---|---|---|---|
| Percentage of Index Participants Who Were Considered a Treatment Success: mITT Population | 91.7 | 89.7 | 28.6 |
Treatment success was defined as the absence of live lice. Non-index participant: Any household member who agreed to participate in the study but was not the youngest household member. Index participant: The youngest household member who was randomized into the study. Therapeutic equivalence evaluation between test (generic ivermectin lotion 0.5%) and reference groups (Sklice \[ivermectin\] lotion 0.5%) was done in this endpoint, hence placebo group was not included.
| percentage of participants | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion |
|---|---|---|
| Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: PP Population | 91.6 | 90.7 |
Treatment success was defined as the absence of live lice. Non-index participant: Any household member who agreed to participate in the study but was not the youngest household member. Index participant: The youngest household member who was randomized into the study.
| percentage of participants | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion | Vehicle Lotion |
|---|---|---|---|
| Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: mITT Population | 92.2 | 91.3 | 25.2 |
Collected over Baseline up to Day 17. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Generic Ivermectin Lotion 0.5% | 0/399 (0%) | 0/399 (0%) | 31/399 (7.8%) |
| Vehicle Lotion | 0/400 (0%) | 0/400 (0%) | 21/400 (5.3%) |
| Sklice (Ivermectin) Lotion | 0/112 (0%) | 0/112 (0%) | 1/112 (0.9%) |
| Event | Generic Ivermectin Lotion 0.5% | Vehicle Lotion | Sklice (Ivermectin) Lotion |
|---|---|---|---|
| Application site pruritusGeneral disorders | 9/399 | 8/400 | 1/112 |
| HeadacheNervous system disorders | 8/399 | 2/400 | 0/112 |
| Eye irritationEye disorders | 2/399 | 2/400 | 0/112 |
| VomitingGastrointestinal disorders | 2/399 | 0/400 | 0/112 |
| Viral upper respiratory tract infectionInfections and infestations | 2/399 | 2/400 | 0/112 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/399 | 0/400 | 0/112 |
| Application site dysaesthesiaGeneral disorders | 1/399 | 2/400 | 0/112 |
| Ocular discomfortEye disorders | 1/399 | 0/400 | 0/112 |
| Abdominal pain upperGastrointestinal disorders | 1/399 | 0/400 | 0/112 |
| NauseaGastrointestinal disorders | 1/399 | 1/400 | 0/112 |
Safety population included all participants who were randomized and received study drug.
| Age, Continuous(years) | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion | Vehicle Lotion | Total |
|---|---|---|---|---|
| Mean | 18.8 ± 15.4 | 16.8 ± 13.9 | 19.0 ± 14.4 | 18.2 ± 14.6 |
| Sex: Female, Male(Participants) | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion | Vehicle Lotion | Total |
|---|---|---|---|---|
| Female | 322 | 324 | 97 | 743 |
| Male | 77 | 76 | 15 | 168 |
| Ethnicity (NIH/OMB)(Participants) | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion | Vehicle Lotion | Total |
|---|---|---|---|---|
| Hispanic or Latino | 344 | 346 | 93 | 783 |
| Not Hispanic or Latino | 55 | 54 | 19 | 128 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion | Vehicle Lotion | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 2 |
| Asian | 11 | 12 | 3 | 26 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 | 4 |
| Black or African American | 6 | 3 | 1 | 10 |
| White | 377 | 377 | 106 | 860 |
| More than one race | 3 | 6 | 0 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Number of live lice(live lice) | Generic Ivermectin Lotion 0.5% | Sklice (Ivermectin) Lotion | Vehicle Lotion | Total |
|---|---|---|---|---|
| Mean | 4.9 ± 4.4 | 4.4 ± 3.5 | 4.5 ± 3.1 | 4.6 ± 3.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Mar 2018, 5 months.
Results were first posted in Dec 2019, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.